VVOSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Vivos Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.13+0.00 (+2.90%)

Close on Oct 19, 2026

Market cap: $2.39M
P/E (TTM): –
Dividend yield: –

Vivos Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Revenue	17	15	14	16	17	13	11
Cost of Revenue	6.90	6.01	5.53	0.20	0.40	0.10	2.74
Gross Profit	11	9.02	8.27	10	13	10	8.66
Research & Development	0.10	0.10	0.10	0.20	0.20	–	–
Selling, General & Admin	29	20	25	34	31	18	18
Selling & Marketing	1.40	1.73	2.47	5.34	5.55	2.31	2.31
General & Administrative	28	18	22	29	26	16	16
Operating Expenses	30	20	26	35	33	22	19
Operating Income	-20	-11	-17	-25	-20	-12	-11
Interest Expense	1.40	–	–	–	0.01	0.10	0.14
Other Non-Operating Income	-1.48	-0.11	-0.21	-0.19	-0.01	–	–
Asset Impairment Charges	–	–	–	–	0.91	0	–
Gain (Loss) on Sale of Assets	–	–	–	-0.04	–	–	-0.06
Legal Settlements	-0.25	–	–	–	–	-3.33	–
Pretax Income	-21	-11	-14	-24	-20	-12	-11
Net Income incl. Noncontrolling Interests	-21	-11	–	–	20	–	–
Minority Interest in Earnings	-0.06	–	–	–	–	–	–
Net Income	-21	-11	-14	-24	-20	-12	-11
Net Income to Common	-21	-11	-14	-24	-20	-18	-12
EPS (Basic)(per share)	-2.07	-2.22	-11.14	-25.90	-24.00	-35.00	-23.75
EPS (Diluted)(per share)	-2.07	-2.22	-11.14	-25.90	-24.00	-35.00	-23.75
Shares Outstanding (Basic, Weighted)(shares)	10	5.02	1.22	0.92	849	0.51	0.49
Shares Outstanding (Diluted, Weighted)(shares)	10	5.02	1.22	0.92	0.85	0.51	0.49
EBITDA	-19	-11	-17	-24	-20	-11	-9.83

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 61.9%
Operating margin: -107.9%
Net margin: -121.8%
Return on equity, FY2025: -655.0%

Financial strength

Current ratio: 0.21
Debt to equity: -2.13
Debt to assets: 33.7%
Cash to current liabilities: 8.7%

Valuation

P/E ratio: –
Price to sales: 0.11
Price to book: –
Dividend yield: –